Information Provided By: 
Fly News Breaks for May 13, 2016
MDCO
May 13, 2016 | 07:35 EDT
Jefferies analyst Biren Amin says The Medicines Co. has a "catalyst-rich" second half of 2016, including the Phase III trials of Carbavance in complicated urinary tract infections and carbapenem resistant enterobacteriaceae infections. The analyst expects both of the trials will be successful and show non-inferiority leading to potential FDA approval. Amin thinks shares could move $3 to $4 per share on positive data readout. He keeps a Buy rating on The Medicines Co. with a $43 price target.
News For MDCO From the Last 2 Days
There are no results for your query MDCO
